Michael Mollerus

We are advising VF on its acquisition

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to customary closing conditions and is expected to close in the second…

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk is advising Emerson Electric Co. on its $1.6 billion acquisition of Open Systems International, Inc. Emerson, headquartered in St. Louis, Missouri, is a global technology and…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Honeywell International Inc. of $2.5 billion aggregate principal amount of its 0.483…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…